GLP-1s
US$ 21.35
compound semaglutide ending Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s FDA Phasing Out Compounded GLP-1
Description
Although conditions such as Stevens-Johnson syndrome are extremely rare, early recognition is critical
This drug isnt approved yet, but big trials are underway all around the globe
It is designed to increase energy use and fat burning, not just suppress appetite
Zheng, B
FDA-approved medication only
Muscle loss can be a great concern due to the rapid weight loss that occurs with these medications
